The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan-dlnk (Datroway) a Trop-2-directed antibody and topoisomerase inhibitor conjugate, as a treatment for breast cancer.  The decision was based on the results of the Phase III TROPION-Breast01 trial which showed a 37% reduction in the risk of disease progression or death vs. chemotherapy.  Datroway was […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!